Effect of cinacalcet on urine calcium excretion and supersaturation in genetic hypercalciuric stone-forming rats

Kidney International

Volumn 69, Issue 9, 2006, Pages 1586-1592

  Bushinsky, D A ^a   LaPlante, K ^a   Asplin, J R ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Calcium receptor; Hypercalciuria; Nephrolithiasis

Indexed keywords

CALCIMIMETIC AGENT; CALCIUM OXALATE; CALCIUM PHOSPHATE DIBASIC; CALCIUM RECEPTOR; CINACALCET; MEMBRANE RECEPTOR; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM INTAKE; CALCIUM URINE LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HYPERCALCIURIA; IDIOPATHIC DISEASE; KIDNEY TUBULE ABSORPTION; METABOLIC DISORDER; NEPHROLITHIASIS; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY;

ANIMALS; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATES; CALCIUM, DIETARY; FEMALE; KIDNEY CALCULI; NAPHTHALENES; PARATHYROID HORMONE; PHOSPHORUS; RATS; RATS, MUTANT STRAINS; RECEPTORS, CALCIUM-SENSING; URINARY CALCULI;

EID: 33646529162     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000324     Document Type: Article

References (40)

1. Monk RD, Bushinsky DA. Kidney stones. In: Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (eds). Williams Textbook of Endocrinology, 10th edn. (Chapter 28) W.B.Saunders: Philadelphia, 2003, pp 1411-1425.
2. Monk RD, Bushinsky DA. Nephrolithiasis and nephrocalcinosis. In: Johnson R, Frehally J (eds). Comprehensive Clinical Nephrology, 2nd edn. Mosby: London, 2003, pp 731-744.
3. Bushinsky DA. Nephrolithiasis. J Am Soc Nephrol 1998; 9: 917-924.
4. Asplin JR, Favus MJ, Coe FL. Nephrolithiasis. In: Brenner BM (ed). The Kidney, 6th edn. (Chapter 40) W.B. Saunders Company: Philadelphia, 2000, pp 1774-1819.
5. Bushinsky DA. Renal lithiasis. In: Humes HD (ed). Kelly's Textbook of Medicine. Lippincott Williams & Wilkens: New York, 2000, pp 1243-1248.
6. Bushinsky DA, Favus MJ. Mechanism of hypercalciuria in genetic hypercalciuric rats: inherited defect in intestinal calcium transport. J Clin Invest 1988; 82: 1585-1591.
7. Kim M, Sessler NE, Tembe V et al. Response of genetic hypercalciuric rats to a low calcium diet. Kidney Int 1993; 43: 189-196.
8. Li X-Q, Tembe V, Horwitz GM et al. Increased intestinal vitamin D receptor in genetic hypercalciuric rats: a cause of intestinal calcium hyperabsorption. J Clin Invest 1993; 91: 661-667.
9. Bushinsky DA, Kim M, Sessler NE et al. Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats. Kidney Int 1994; 45: 58-65.
10. Bushinsky DA, Grynpas MD, Nilsson EL et al. Stone formation in genetic hypercalciuric rats. Kidney Int 1995; 48: 1705-1713.
11. 3 in bone from genetic hypercalciuric rats. Am J Physiol (Cell Physiol) 1996; 271: C130-C135.
12. Bushinsky DA, Bashir MA, Riordon DR et al. Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats. Kidney Int 1999; 55: 602-612.
13. Asplin JR, Bushinsky DA, Singharetnam W et al. Relationship between supersaturation and crystal inhibition in hypercalciuric rats. Kidney Int 1997; 51: 640-645.
14. Tsuruoka S, Bushinsky DA, Schwartz GJ. Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int 1997; 51: 1540-1547.
15. Bushinsky DA, Neumann KJ, Asplin J, Krieger NS. Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 1999; 55: 234-243.
16. 3: a new characteristic of genetic hypercalciuric stone-forming rats. J Clin Invest 1998; 101: 2223-2232.
17. Evan AP, Bledsoe SB, Smith SB, Bushinsky DA. Calcium oxalate crystal localization and osteopontin immunostaining in genetic hypercalciuric stone-forming rats. Kidney Int 2004; 65: 154-161.
18. Bushinsky DA, Parker WR, Asplin JR. Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2000; 57: 550-560.
19. Bushinsky DA, Grynpas MD, Asplin JR. Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone forming rats. Kidney Int 2001; 59: 1415-1423.
20. Bushinsky DA, Asplin JR, Grynpas MD et al. Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 2002; 61: 975-987.
21. 3 in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol 2005; 16: 1300-1308.
22. Bushinsky DA, Asplin JR. Thiazides reduce brushite, but not calcium oxalate, supersaturation and stone formation in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol 2005; 16: 417-424.
23. Karnauskas AJ, van Leeuwen JP, van den Bemd GJ et al. Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats. J Bone Min Res 2005; 20: 447-454.
24. Hagler L, Herman RH. Oxalate metabolism. I. Am J Clin Nutr 1973; 26: 758-765.
25. Riccardi D, Park J, Lee WS et al. Cloning and functional expression of a rat kidney extracellular calcium/polyvalent cation-sensing receptor. Proc Natl Acad Sci USA 1995; 92: 131-135.
26. Frick KK, Bushinsky DA. Molecular mechanisms of primary hypercalciuria. J Am Soc Neph 2003; 14: 1082-1095.
27. Goodman WG. Calcium-sensing receptors. Semin Nephrol 2004; 23: 17-24.
28. Brown EM, MacLeod RJ. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001; 81: 239-297.
29. Favus MJ, Karnauskas AJ, Parks JH, Coe FL. Peripheral blood monocyte vitamin D receptor levels are elevated in patients with idiopathic hypercalciuria. J Clin Endocrinol Metab 2004; 89: 4937-4943.
30. Canaff L, Hendy GN. Human calclium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002; 277: 30337-30350.
31. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Neph 2003; 14: 575-583.
32. Drueke TB. Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 2004; 19: 20-26.
33. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
34. Bushinsky DA. Calcium, magnesium, and phosphorus renal handling and urinary excretion. In: Favus MJ (ed). Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th edn. (Chapter 15) American Society for Bone and Mineral Research: Washington, DC, 2003, pp 97-105.
35. Friedman EA. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Intl Suppl 2005; 96: S2-S6.
36. Nemeth EF, Heaton WH, Miller M et al. Pharmocodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004; 308: 627-635.
37. Kumar GN, Sproul C, Poppe L et al. Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. Drug Metab Dispos 2004; 32: 1491-1500.
38. Finlayson B. Calcium stones: some physical and clinical aspects. In: David DS (ed). Calcium Metabolism in Renal Failure and Nephrolithiasis. Wiley: New York, 1977, pp 337-382.
39. Werness PG, Brown CM, Smith LH, Finlayson B. EQUIL2: a BASIC computer program for the calculation of urinary saturation. J Urol 1985; 134: 1242-1244.
40. Brown CM, Ackermann DK, Purich DL. EQUIL93: a tool for experimental and clinical urolithiasis. Urol Res 1994; 22: 119-126.